Some outfit called Relationship Science....never heard of them.  I doubt they have much of a footprint, if any....and the analysis is quite, uhm....I guess I'll say its entertaining, especially the bit about Fundamentals that says the company is "cash rich" which I will bold and underline:

CANADIAN DAILY STOCK REPORT

Resverlogix Corp. (TSX:RVX), Canada's 6th largest Biotechnology company by market cap, has lifted 8.0c (4.0%) from its last trading session of May 11 to close at CAD2.09. Compared with the S&P/TSX 60 Index which fell 0.2 points (0.02%) in the day, the relative price increase was 4.0%. The volume was 0.6 times the average daily trading volume of 83,617 shares. In the Canadian market of 1,855 stocks and 78 units traded today, the stock has a 4-month relative price strength of 83 indicating it has outperformed 83% of the market. A price rise combined with a high relative strength is a bullish signal.

SECTION 1

RESVERLOGIX BULLISH SIGNALS

1.1 Fundamentals:

+ The company is cash rich with Cash to Market Capitalisation at 12.7%.

+ Total Liabilities/EBITDA of 3.7 is comfortably below the Joseph Piotroski benchmark of 5.

1.2 Technicals:

May 12, 2017: CAD 1 equals USD 0.73

+ Compound Annual Growth Rate (CAGR) in USD = 2.3%

+ 5 years Multiplier in USD = 1.121x

+ 5 years ago CAD 1 equalled USD 0.9994

+ The present value of USD1,000 (PV1000) invested five years ago in Resverlogix is $US1,121, for a capital gain of $US121.

Present Value of USD1,000 invested 5 years ago:

+ Compound Annual Growth Rate (CAGR) in CAD = 9.0%

+ 5 years Multiplier in CAD = 1.537x

+ The present value of CAD1,000 (PV1000) invested five years ago in Resverlogix is CAD1,537, for a capital gain of CAD537.

+ The present value of CAD1,000 (PV1000) invested one year ago in Resverlogix is CAD1,608, for a capital gain of CAD608.

Uptrend: The stock rose 4.0% on high volatility today and expanding price range.

1.3 High Performance Indicators:

SECTION 2

RESVERLOGIX BEARISH SIGNALS

2.1 Fundamentals:

+ Tobin's Q Ratio, defined as MCap divided by Total Assets, is 5.5. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.

2.2 Technicals:

+ The stock is overbought according to the Williams % R indicator of -3.4, suggesting the price is close to its 14-day high of CAD2.10.

Overbought/Bearish/Resistance Signals:

2.3 Low Performance Indicator:

SECTION 3

PRICE VOLUME DYNAMICS

3.1 Volatility:

+ Resverlogix is at a discount of 15.4% to its 12-month high of CAD2.47 on October 05, 2016. It is also at a premium of 90.0% to the 12-month low of CAD1.10 on June 27, 2016.

3.2 Performance Indicator:

3.3 Beta:

+ Beta: the Beta of Resverlogix stock is 0.1. A Beta lower than 1 suggests this is a low risk, low return stock with volatility less than that of the market.

3.4 Aggregate Volumes, Prices and Turnover Period:

The turnover rate in the 12 months to date was 8.9% (or a turnover period of 11 years 2 months). This average length of ownership of the stock at 5.8 times the average holding period of 1 year 11 months for stocks in the S&P/TSX 60 Index suggests a larger number of core investors, making a long-term investment safer.

+ Aggregate volume: there were 48,965 shares of Resverlogix worth CAD102,234 traded today. The aggregate volume was 0.8 times average trading of 64,000 shares.

+ OTC Pink: RVXCF.PINKSHEETS 2,895 [VI of 0.2] volume 5.91% of aggregate. Price: $US1.50. Using the current exchange rate of USD1 equals 1.3697CAD, The shares are at a 1.7% discount to the close price on Toronto.

+ Toronto: RVX.TSX 46,070 [VI of 0.9] volume 94.09% of aggregate. Price: CAD2.09.

[Volume Index or VI in brackets; 1 is average]

SECTION 4

Global Rank [out of 47,210 stocks] and Rank in the American Region [out of 12,777 stocks]

DescriptionValueGlobal RankIn Am RegionMCap (US$)160.9M19,0974,789Total Assets (US$)29.3M30,6466,635Net Profit (US$)(14.4M)38,1488,994PV$1000 (1Year) US$*1,5178,5052,384US$* Change (1Year) %43.98,0912,259

* 1 year ago CAD 1 = USD 0.78

May 12, 2017: CAD 1 equals USD 0.73

SECTION 5

RESVERLOGIX FINANCIALS

Financials Summary

SECTION 6

RESVERLOGIX PROFILE

6.1 Activities

Resverlogix Corp is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I.

6.2 Industry & Sector

* NEC: Not elsewhere classified

6.3 Top Management

The chief executive officer and chairman is Donald Mccaffrey and the chief financial officer is A. Brad Cann.

6.4 Issued Capital

Based on 105,640,544 issued shares the market capitalisation is CAD220.8 million (US$160.9 million).

SECTION 7

STOCK BUZZ

Corporate Wire

February 23: Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial

February 24: Research Reports Initiated on Healthcare Stocks Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris

March 15: Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

March 17: Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities

March 29: Research Reports Initiated on Healthcare Stocks BELLUS Health, Resverlogix, Helius Medical Technologies, and IntelliPharmaCeutics International

To view Recent Company Headlines, click

Contact: (403) 254-9252

Exchange: Toronto Stock Exchange

Industry [NAICS]: 325414

Country of Incorporation: Canada

State/Province/Country: Canada

Physical Address: 279 Midpark Way SE, Suite 202, Calgary, AB, CA, T2X 1M2

ISIN: CA76128M1086

CIK: Resverlogix Corp.

PermID: 4295862411

T:RVX; TSE:RVX; N:RVX; CN:RVX; RVX.TO

Resverlogix Corp

Source: www.BuySellSignals.com